$PMHS
Polomar Health Services, Inc.

2024 Q2 Form 10-K Financial Statement

#000149315224014594 Filed on April 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2023 Q4 2023
Revenue $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $18.41K $269.8K
YoY Change 24.93%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $20.12K $18.40K $269.8K
YoY Change -77.88% 24.93%
Operating Profit -$20.12K -$18.40K -$269.8K
YoY Change -77.88% 48.71%
Interest Expense $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$146.7K
YoY Change
Pretax Income -$127.6K -$416.5K
YoY Change 129.96%
Income Tax
% Of Pretax Income
Net Earnings -$20.12K -$127.6K -$416.5K
YoY Change -77.88% 129.96%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 -$0.02
Diluted Earnings Per Share $0.00 $0.00 -$0.02
COMMON SHARES
Basic Shares Outstanding 109.1M shares 109.1M shares 17.43M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $240.00 $240.00
YoY Change -99.89%
Cash & Equivalents $294.00 $224.00
Short-Term Investments
Other Short-Term Assets $0.00 $0.00
YoY Change -100.0%
Inventory $3.459K
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $294.00 $244.00 $240.00
YoY Change -99.77% -99.91% -99.91%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $94.83K
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $294.00 $244.00 $240.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $294.00 $244.00 $240.00
YoY Change -99.77% -99.91% -99.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.78K $13.78K
YoY Change 175.05%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $103.0K $13.78K $13.78K
YoY Change 634.11% -81.55% -81.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $103.0K $13.78K $13.78K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $103.0K $13.78K $13.78K
YoY Change 634.11% -81.55% -81.56%
SHAREHOLDERS EQUITY
Retained Earnings -$1.487M -$1.398M
YoY Change 27.94% 42.42%
Common Stock $109.1K $109.1K
YoY Change 0.53% 1.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$102.7K -$13.54K -$13.54K
YoY Change
Total Liabilities & Shareholders Equity $294.00 $244.00 $240.00
YoY Change -99.77% -99.91% -99.91%

Cashflow Statement

Concept 2024 Q2 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$20.12K -$127.6K -$416.5K
YoY Change -77.88% 129.96%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$10.14K -$371.9K
YoY Change 808.54%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $216.2K
YoY Change -5.82%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.700K $146.5K
YoY Change -45.04%
NET CHANGE
Cash From Operating Activities -10.14K -$371.9K
Cash From Investing Activities
Cash From Financing Activities -4.700K $146.5K
Net Change In Cash -14.84K -$225.4K
YoY Change -199.89%
FREE CASH FLOW
Cash From Operating Activities -$10.14K -$371.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
usd
CY2023Q4 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
usd
CY2023Q4 us-gaap Payable Common Stock Redeemed
PayableCommonStockRedeemed
usd
CY2023 us-gaap Revenues
Revenues
usd
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2023 us-gaap Gross Profit
GrossProfit
usd
CY2023 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
usd
CY2022 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
usd
CY2022 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
usd
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2022 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2023 us-gaap Interest Paid
InterestPaid
usd
CY2022 us-gaap Interest Paid
InterestPaid
usd
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023 TRFE Return And Cancellation Of Common Stock
ReturnAndCancellationOfCommonStock
usd
CY2022 TRFE Forgiveness Of Receivable Related Party
ForgivenessOfReceivableRelatedParty
usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
38853145 usd
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
109138049 shares
CY2023 dei Auditor Firm
AuditorFirmId
6580
CY2023 dei Auditor Name
AuditorName
GreenGrowth CPAs
CY2023 dei Auditor Location
AuditorLocation
Los Angeles, California
CY2023Q4 us-gaap Cash
Cash
244 usd
CY2022Q4 us-gaap Cash
Cash
225619 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
30000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5865 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
244 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
261484 usd
CY2023Q4 us-gaap Assets
Assets
244 usd
CY2022Q4 us-gaap Assets
Assets
261484 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13783 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5012 usd
CY2022Q4 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
69703 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13783 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
74715 usd
CY2023Q4 us-gaap Liabilities
Liabilities
13783 usd
CY2022Q4 us-gaap Liabilities
Liabilities
74715 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
500 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
500 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109138049 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109138049 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
107582614 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
107582614 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
109138 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
107582 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1275156 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1023476 usd
CY2022Q4 us-gaap Payable Common Stock Redeemed
PayableCommonStockRedeemed
37044 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1398333 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-981833 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13539 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
186769 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
244 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
261484 usd
CY2022 us-gaap Revenues
Revenues
34526 usd
CY2022 us-gaap Gross Profit
GrossProfit
34526 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
269830 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
215979 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
269830 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
215979 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-269830 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-181453 usd
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
138 usd
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-53 usd
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
191 usd
CY2023 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
146617 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-146670 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
329 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-416500 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-181124 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17429854 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
452543027 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-85146 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-181124 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
186769 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
186769 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
216192 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-416500 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13539 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13539 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-416500 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-181124 usd
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
20000 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
173995 usd
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10000 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
30000 usd
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-5865 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
5865 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8771 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2060 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-371864 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40934 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
216192 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
229544 usd
CY2023 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
42564 usd
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
37009 usd
CY2023 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
112267 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
146489 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
266553 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-225375 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
225619 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
225619 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
244 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
225619 usd
CY2022 TRFE Return And Cancellation Of Common Stock
ReturnAndCancellationOfCommonStock
95000 usd
CY2023 TRFE Forgiveness Of Receivable Related Party
ForgivenessOfReceivableRelatedParty
146617 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zCfxB1H2M3E2" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates.</span></p>
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
224 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1398333 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-416500 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-371864 usd
CY2023Q3 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
37432 usd
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
1398333 usd
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
981833 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
293650 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
206185 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
293650 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
206185 usd
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
1398333 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2022Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On June 3, 2022, the Board authorized the execution of a reverse split of the issued and outstanding shares of the Corporation’s common stock at a ratio of up to one post-split share per two thousand pre-split shares (1:2,000) .
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109138049 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109138049 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
107582614 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
107582614 shares

Files In Submission

Name View Source Status
0001493152-24-014594-index-headers.html Edgar Link pending
0001493152-24-014594-index.html Edgar Link pending
0001493152-24-014594.txt Edgar Link pending
0001493152-24-014594-xbrl.zip Edgar Link pending
audit_001.jpg Edgar Link pending
audit_002.jpg Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
trfe-20231231.xsd Edgar Link pending
form10-k_htm.xml Edgar Link completed
trfe-20231231_def.xml Edgar Link unprocessable
trfe-20231231_lab.xml Edgar Link unprocessable
trfe-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
trfe-20231231_cal.xml Edgar Link unprocessable